• ๋ฉด์—ญ์–ต์ œ์„ฑ ์งˆ๋ณ‘์˜ ๋งˆ์ง€๋ง‰
    • MD, LL, RE์˜ ๊ณตํ†ต์  : ๋ฉด์—ญ ์–ต์ œ, tumor formation
    • ์ฐจ์ด์  : MDV๋Š” herpesvirus, LL๊ณผ REV๋Š” retrovirus โ†’ ์•” ๋ฐœ์ƒ ๊ธฐ์ „๋„ ์กฐ๊ธˆ์”ฉ ๋‹ค๋ฆ„
 

โ… . Introduction

  • Reticuloendotheliosis(RE, ์„ธ๋ง๋‚ดํ”ผ์ฆ)์€ REV group์— ์˜ํ•ด ๋‚˜ํƒ€๋‚˜๋Š” ๋ณ‘๋ฆฌ์  syndrome์„ ํ†ต์นญ.
    • REV group : Retrovirus ์ค‘์—์„œ๋„ reticuloendotheliosis๋ผ๋Š” ๋ณ‘์›์„ฑ์„ ๋‚˜ํƒ€๋‚ด๋Š” virus์˜ group.
    • REV group์€ strain T, chick syncytial virus, duck infectious anemia virus, spleen necrosis virus ๋“ฑ์ด ์žˆ์Œ
  • ์ด syndrome์—๋Š” 3๊ฐ€์ง€๋ฅผ ํฌํ•จ
    1. acute reticulum cell neoplasia (๊ธ‰์„ฑ ์„ธ๋ง์„ธํฌ ์ข…์–‘ํ™”) : by strain T mixture
      • ๊ณ ์œ ์˜ oncogene์„ host cell์— ์‚ฝ์ž…ํ•˜์—ฌ ์ข…์–‘ํ™”
    2. runting disease syndrome (๋ฐœ์œก๋ถ€์ „ ์ฆํ›„๊ตฐ) : by non-defective REV
    3. chronic neoplasia of lymphoid and other tissues (๋งŒ์„ฑ ์ข…์–‘ํ™”) : by non-defective REV
      • ์ง์ ‘์ ์œผ๋กœ oncogene์„ ์‚ฝ์ž…ํ•˜๋Š” ๊ฒŒ ์•„๋‹ˆ๋ผ, promoter๋ฅผ ์‚ฝ์ž…(๋ณต์ œ์˜ trigger๋ฅผ ์‚ฝ์ž…ํ•˜๋Š” ์…ˆ) โ†’ 15์ฃผ ์ •๋„์˜ ์˜ค๋žœ ์‹œ๊ฐ„์— ๊ฑธ์ณ ์ข…์–‘์ด ํ˜•์„ฑ๋จ.
  • Strain T mixture : defective Strain T + nondefective helper virus
    • ์ตœ์ดˆ์˜ REV ๋ถ„๋ฆฌ์ฃผ์ธ strain T๋Š” ์น ๋ฉด์กฐ ๋‚ด๋ถ€์žฅ๊ธฐ์˜ lymphoma์—์„œ ๋ถ„๋ฆฌ๋จ.
    • strain T : replication defective virus. ์œ ์ „์ž๋ฅผ ์™„๋ฒฝํžˆ ๋ณด์œ ํ•˜์ง€ ์•Š์•„ ์Šค์Šค๋กœ๋Š” ๋ณต์ œํ•˜์ง€ ๋ชปํ•˜์ง€๋งŒ, oncogene(v-rel)์„ ๊ฐ€์ง€๊ณ  ์žˆ์Œ.
    • helper virus (REV-A) : oncogene์€ ์—†์ง€๋งŒ non-defectiveํ•˜๊ธฐ ๋•Œ๋ฌธ์— CEF์—์„œ ๋ณต์ œ ๊ฐ€๋Šฅ.
    • ์‹คํ—˜์‹ค์—์„œ ๋‘˜์˜ mixture๋ฅผ ์ œ์ž‘(๋ณ‘์›์„ฑ์ด ๋†’์€ ๋ฐฉํ–ฅ์œผ๋กœ ์ง„ํ™”)
    • ๊ณ ์œ ์˜ oncogene์œผ๋กœ ๊ธ‰์„ฑ ๋ฐœ์•” ๊ฐ€๋Šฅ โ†’ acute reticulum cell neoplasia๋ฅผ ์œ ๋ฐœํ•˜๋ฉฐ, ์‹คํ—˜์‹ค strain์œผ๋กœ ์ž์—ฐ ์ƒํƒœ์—์„œ๋Š” ๋ณด๊ณ ๋˜์ง€ ์•Š์Œ.
  • ์Šค์Šค๋กœ ๋ณต์ œ ๊ฐ€๋Šฅํ•œ nondefective REV๋Š” runting disease์™€ chronic neoplastic disease๋ฅผ ์œ ๋ฐœ, ์ž์—ฐ ์ƒํƒœ์—์„œ ๋ฐœ์ƒ ๊ฐ€๋Šฅ
  • ์‹ฌ๊ฐํ•œ ๊ฒฝ์ œ์  ๋ฌธ์ œ๋ฅผ ๋ฐœ์ƒ์‹œํ‚ค์ง€๋Š” ์•Š์Œ. (MD์™€ LL์— ๋น„ํ•ด ๋ฐœ์ƒ ๋นˆ๋„๊ฐ€ ๋‚ฎ๊ธฐ ๋•Œ๋ฌธ)
  • ๋Œ€๋ถ€๋ถ„์˜ REV๋Š” poultry vaccine์˜ ์˜ค์—ผ์ด ์ „ํŒŒ์— ๊ฐ€์žฅ ๊ธฐ์—ฌ. (defective๋“  non-defective๋“ , retrovirus๊ธฐ ๋•Œ๋ฌธ์— ๋‹ค๋ฅธ ์œ ์ „์ž์— ์‚ฝ์ž…๋จ โ†’ ๋‹จ๋ฐฑ์งˆ ํ•ฉ์„ฑ โ†’ RE syndrome ๋‚˜ํƒ€๋‚ผ ์ˆ˜ ์žˆ์Œ.
    • size๊ฐ€ ํฐ ์œ ์ „์ฒด์— ์‚ฝ์ž…๋  ์ˆ˜ ์žˆ์Œ: Herpes(Marek, ILT), fowl poxvirus ๋“ฑ โ†’ Marek vaccine ๋“ฑ์— ์˜ํ•ด ๊ฐ€์žฅ ํ”ํžˆ ์ „ํŒŒ.
    • ๋ชจ๊ธฐ, ํŒŒ๋ฆฌ์— ์˜ํ•œ vector, ์ˆ˜ํ‰์ „ํŒŒ๋„ ๋А๋ฆฌ๊ณ  ๋“œ๋ฌผ์ง€๋งŒ ๊ฐ€๋Šฅ. ์ˆ˜์ง์ „ํŒŒ๋„ ์„ฑ๋ฆฝํ•จ.
  • REV์— ์˜ํ•ด ๋‚˜ํƒ€๋‚˜๋Š” ์ข…์–‘์€ MD, LL๊ณผ๋„ ์œ ์‚ฌ.
  • ์‚ฌ๋žŒ์ด๋‚˜ ํฌ์œ ๋™๋ฌผ์—์„œ neoplastic disease ์œ ๋ฐœ์— ์ข‹์€ ๋ชจ๋ธ.

โ…ก. History

1) Incidence, distribution

  • Initial isolate์€ 1958๋…„ Turkey์—์„œ strain T ๋ถ„๋ฆฌ.
  • nondefective REV๋Š” ubiquitousํ•˜๋‹ค๊ณ  ํ•  ์ˆœ ์—†์ง€๋งŒ, ๋‹ญ๊ณผ ์น ๋ฉด์กฐ์—์„œ ๊ฝค ํผ์ ธ ์žˆ์Œ. ๋ฐœ์ƒ๋ฅ ์€ ๋†’์ง€ ์•Š์Œ.
  • clinical RE๋Š” ํ”ํ•˜์ง„ ์•Š์Œ.
    • ์น ๋ฉด์กฐ : chronic์ด ์ž์—ฐ์  ๋ฐœ์ƒ, ์‚ฐ๋ฐœ์ ์œผ๋กœ ๋ณด๊ณ ๋˜๋Š” ์ •๋„
    • ๋‹ญ : REV-contaminated MD vaccine์— ์˜ค์—ผ๋œ ์‚ฌ๋ก€ / REV-contaminated fowl pox vaccine / ๊ธฐํƒ€ ๋‹ค๋ฅธ ๋ฐฑ์‹  ์˜ค์—ผ
    • chronic neoplasia : ๊ธฐํƒ€ ์กฐ๋ฅ˜์—์„œ๋„ ๋“œ๋ฌผ์ง€๋งŒ ๋‚˜ํƒ€๋‚จ.
    • runting disease : REV-contaminated ๋ฐฑ์‹ ์— ์˜ํ•  ๋งŽ์ด ๋ฐœ์ƒ. Poor growth, ๊นƒํ„ธ ๋ชจ์–‘ ์ด์ƒ(Nakanuke syndrome), ์„ ์œ„์—ผ, ๋ฉด์—ญ ์–ต์ œ.
  • REV ํ•ญ์ฒด๋Š” 60-80% ์ •๋„ ๋ณด๊ณ ๋จ.
    • integration ๋˜์—ˆ๋‹ค ํ•˜๋”๋ผ๋„, ํ•„์ˆ˜์œ ์ „์ž์ธ gag, pol, env์ด full set๋กœ ์žˆ์ง€ ์•Š์œผ๋ฉด clinical sign์€ ๋‚˜ํƒ€๋‚˜์ง€ ์•Š์Œ.
    • but ํ•ญ์ฒด ๊ฒ€์‚ฌ๋Š” ํŠน์ • ๋‹จ๋ฐฑ์งˆ์„ targetํ•˜๊ธฐ ๋•Œ๋ฌธ์—, gag/pol/env ์ค‘ ํ•˜๋‚˜๋ผ๋„ ์žˆ์œผ๋ฉด ํ•ญ์ฒด ๋ฐœํ˜„์œจ์ด ๋†’๊ฒŒ ์ธก์ •๋  ์ˆ˜ ์žˆ์Œ.

โ…ข. Etiology

1) Classification

  • family Retroviridae
    • subfamily Orthoretrovirinae
      • genus Gammaretrovirus

2) Properties

  • ssRNA, enveloped, ์ง๊ฒฝ 100nm.
  • structural proteins : gag-pol-env
    • gag : assembly, 3๊ฐ€์ง€ ๋‹จ๋ฐฑ์งˆ์„ ์กฐํ•ฉ (p12, pp18, pp20, p30, p10, p30)
    • pol : RNA-directed DNA polymerase (reverse transcripase)
    • env : envelope์„ ๋งŒ๋“ฆ, epitope ๊ตฌ์„ฑ (gp90, gp20, gp90)
  • defective๋„, non-defective๋„ 3๊ฐ€์ง€ ๊ตฌ์กฐ ๋‹จ๋ฐฑ์งˆ์€ ๋ชจ๋‘ ๋ณด์œ .
  • oncogene v-rel์€ strain T์—๋งŒ ์กด์žฌํ•˜๋ฉฐ, ๊ธ‰์„ฑ ๋ฐœ์•”์„ ์œ ๋ฐœํ•˜๊ฒŒ ํ•จ. (๊ทธ๋ฆผ์˜ B)

  • ์ผ๋ฐ˜ ์†Œ๋…์ œ์— ์ทจ์•ฝํ•จ (envelope)

3) Replication

  • Non-defective strain (์ผ๋ฐ˜์ ์ธ ๋ฐฉ๋ฒ•)
    • attachment : env์ด ๊ด€์—ฌ
    • fusion : cell membrane + viral membrane์˜ direct fusion
    • replication : pol์— ์˜ํ•ด ํ˜•์„ฑ๋œ polymerase์— ์˜ํ•ด (RNA-directed DNA-polymerase)
    • budding : plasma membrane์„ ๊ฑฐ์นจ
  • Defective strain
    • replication ๋ชปํ•˜์ง€๋งŒ, oncogene(v-rel)์„ ๊ฐ€์ง.

4) Strain classification

  • ํ•œ ๊ฐ€์ง€์˜ serotype๋งŒ ์กด์žฌํ•จ.
  • ๋‹ค์–‘ํ•œ ์ข…์˜ ์กฐ๋ฅ˜์— ๊ฐ์—ผ.

5) Laboratory Host System

  • ์–ด๋ฆฐ ๋ณ‘์•„๋ฆฌ, ์–ด๋ฆฐ ์กฐ๋ฅ˜๋ฅผ ์‚ฌ์šฉ
  • cell culture
    • fibroblast cell์ด ์ œ์ผ ์ข‹์Œ. (CEF, DEF)
    • QT35, D17 ๊ฐ™์€ continuous line cells

โ…ฃ. Pathogenesis

Tumor Formation

  • Slow transforming (chronical neoplasia)
    • full size REV๊ฐ€ ํŠน์ • ์„ธํฌ(MYC)์˜ ์œ ์ „์ž ์•ž์œผ๋กœ insertion ๋˜์–ด promoter๋กœ ์ž‘์šฉ.
    • ๊ณ„์† ๋ถ„ํ™”๋˜์–ด ์ข…์–‘์ด ๋จ.
    • ๋งค์šฐ ์˜ค๋ž˜ ๊ฑธ๋ฆผ. ๊ฐ์—ผ ํ›„ 16์ฃผ ์ด์ƒ ์†Œ์š”. (promoter๋งŒ ์‚ฝ์ž…ํ•ด์„œ ์ˆ™์ฃผ์„ธํฌ์˜ ๋ถ„ํ™”๋ฅผ ์ž๊ทนํ•˜๋Š” ๊ฒƒ์ด๊ธฐ ๋•Œ๋ฌธ์—)
  • Acute transforming
    • v-rel๊ณผ ๊ฐ™์€ oncogene์ด ์ง์ ‘์ ์œผ๋กœ ์ˆ™์ฃผ์„ธํฌ์— ์‚ฝ์ž… โ†’ oncogene์ด ๋ฐœํ˜„๋˜์–ด ํŠน์ • ์œ ์ „์ž๋ฅผ ๊ณผ์ฆ์‹
    • 8์ฃผ ์ด๋‚ด๋กœ ๊ธ‰ํ•˜๊ฒŒ ๋ฐœ๋ฐœ

1) Clinical signs

  • ์–ด๋ฆฐ ์—ฐ๋ น์—์„œ ๊ฐ์—ผ๋˜๋ฉด ์ฃผ๋กœ runting syndrome์ด ๋‚˜ํƒ€๋‚˜ ๋ฐœ์œก ์ €ํ•˜, ๊นƒํ„ธ ์ด์ƒ(๋‚˜์นด๋ˆ„์ผ€๋ณ‘)
  • chronic lymphoma ๊ด€๋ จ ์ฆ์ƒ์€ ๋“œ๋ฌพ Nakanuke syndrome / helicopter syndrom (๊นƒํ„ธ ๋ถˆ๋Ÿ‰)

2) Gross lesions

  • Runting syndrome์€ ํŠน์ง•์ ์œผ๋กœ ==thymus์™€ bursa์˜ ์œ„์ถ•(atrophy) ๋‚˜ํƒ€๋‚จ โ†’ T cell, B cell์˜ ๋ถ„ํ™” ์ง€์—ฐ โ†’ ๋ฉด์—ญ ์ €ํ•˜(immunodepressed)==๊นŒ์ง€ ์ด์–ด์ง
  • Tumor์ด ์—†์–ด๋„, ๋ถ€๊ฐ€์ ์ธ ์ฆ์ƒ์œผ๋กœ peripheral nerves์˜ ๋น„๋Œ€, ๊นƒํ„ธ ๋ถˆ๋Ÿ‰(๋‚˜์นด๋ˆ„์ผ€), ์„ ์œ„์—ผ, ์žฅ์—ผ, ๋นˆํ˜ˆ์ด ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Œ.
    • gizzard์˜ ์—ผ์ฆ์€ ๊ด€๋ จ ์—†์Œ.
  • chronic lymphoma syndrome : ALV์™€ ์œ ์‚ฌํ•œ ์ฆ์ƒ
    • ALV๋„, REV๋„ c-myc gene๋ฅผ ๊ฐ‘์ž๊ธฐ triggerํ•ด์„œ ์ข…์–‘ ์œ ๋ฐœ
  • ๋‹ค์–‘ํ•œ ํ˜•ํƒœ์˜ lymphoma๊ฐ€ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Œ. MD์™€ ๋‹ฎ์€ ์–‘์ƒ but F๋‚ญ ์ข…์–‘์€ ๊ฑฐ์˜ ๊ด€์ธก๋˜์ง€ ์•Š์Œ. (๊ทธ๋Ÿฌ๋‚˜ ์œก์•ˆ์œผ๋กœ MD์™€ RE์˜ ๊ตฌ๋ถ„์€ ๊ฑฐ์˜ ๋ถˆ๊ฐ€๋Šฅ)

โ…ค. Epizootiology

  • ์ˆ˜์ง, ์ˆ˜ํ‰ ์ „ํŒŒ๊ฐ€ ๊ฐ€๋Šฅ
  • ๋ชจ๊ธฐ, ํŒŒ๋ฆฌ๊ฐ€ vector๋กœ ์ž‘์šฉ
  • ์‚ฌ๋žŒ ์†์— ์˜ํ•œ ์ „ํŒŒ๋„ ๊ฐ€๋Šฅ

โ…ฅ. Diagnosis

  • ์šฐ๋ฆฌ๋‚˜๋ผ ์ƒํ™ฉ์—์„œ ์ข…์–‘์ด ๋ฐœ์ƒํ•˜๋ฉด ๊ฑฐ์˜ Marek์ด์ง€๋งŒ..
  • ์ •ํ™•ํ•˜๊ฒŒ ์ง„๋‹จํ•˜๊ณ  ์‹ถ์œผ๋ฉด isolation & identification
    • Whole blood, spleen, tumor tissues๊ฐ€ ๊ฐ€์žฅ ๊ถŒ์žฅ
    • QT35, DEF์—์„œ๋„ ์ฆ์‹ํ•  ์ˆ˜ ์žˆ์Œ
  • antigen detection : PCR
  • serology
    • ํ›„๋Œ€๋กœ REV ์ดํ–‰๋˜๋Š”์ง€ ํ™•์ธํ•˜๊ธฐ ์œ„ํ•จ
    • ์ž„์ƒ์ ์œผ๋กœ ํฐ ์˜๋ฏธ๋ฅผ ๊ฐ€์ง€๋Š” ๋ฐฉ๋ฒ•์€ ์•„๋‹˜
    • ํŠน์ • RE virus ์ค‘ ์ผ๋ถ€ ์œ ์ „์ž๋งŒ ์žˆ์–ด๋„ ํ•ญ์ฒด ๋ฐ˜์‘์ด ๋‚˜์˜ฌ ์ˆ˜ ์žˆ์–ด, ํ•ญ์ฒด๋Š” ์–‘์„ฑ์ธ๋ฐ ์ฆ์ƒ์€ ์Œ์„ฑ์ผ ์ˆ˜ ์žˆ๊ธฐ ๋•Œ๋ฌธ

โ…ฆ. Intervention strategies

  • ์ข…๊ณ„ ์ˆ˜์ค€์—์„œ antibody surveillance๋Š” ์œ ์˜๋ฏธ
    • ๋ชจ๋“  ์œ ์ „์ž๋ฅผ ๊ฐ€์ง„ ํ˜•ํƒœ๋ฉด ๊ทผ์ ˆ ํ•„์š”
    • full gene์ด ์•„๋‹ˆ๋ผ๋ฉด, ๋‚œ๊ณ„๋Œ€๊ฐ์—ผ์œผ๋กœ ํ›„๋Œ€์— ํ”ผํ•ด๋ฅผ ๋ฏธ์น˜์ง€๋Š” ์•Š์Œ
  • ๋ฐฑ์‹ 
    • ๋‹ค์–‘ํ•œ ์‹œ๋„๋Š” ์žˆ์ง€๋งŒ, ์ƒ์šฉํ™”๋œ ๊ฑด ์—†์Œ
  • ์น˜๋ฃŒ : ์—†์Œ. (ํ•ญ์ƒ์ œ๋กœ ๋ฉด์—ญ ์–ต์ œ์— ์˜ํ•œ ๊ธฐํƒ€ ์„ธ๊ท ์„ฑ ๊ฐ์—ผ์„ ๋ง‰๋Š” ์ •๋„)
  • eradication์ด ์ค‘์š”

+ Other spontaneous Tumors

  • Keratoacanthomas
  • Melanoma